Share your opinion and earn yourself a free Motley Fool premium report!

We are looking for Fools to join a 75 minute online independent market research forum on 15th / 16th December.

To find out more and express your interest please click here

3 High-Yield Dividend Stocks For The Next Bear Market: GlaxoSmithKline plc, Pearson plc And G4S plc

Should you buy shares in GlaxoSmithKline plc (LON:GSK), Pearson plc (LON:PSON) & G4S plc (LON:GFS) for their dividends?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

When stock markets go awry, high yield stocks tend to outperform the broader market. The high-yielding dividend stocks that perform best in a downturn are so-called defensive ones. These are stocks in companies that provide goods and services always needed throughout the business cycle, enabling them to generate stable profits year after year.

Here are three high-yield stocks that could protect your portfolio in a bear market.

Controversial

GlaxoSmithKline (LSE: GSK) may be a controversial pick given its poor earnings trend. But as healthcare needs are continually rising, GSK remains a big growth opportunity. And despite recent weak results, it maintains a strong competitive position and has robust free cash flow generation.

Early signs of recovery are also beginning to show, with quarterly sales figures highlighting strong growth from its new pharmaceutical products, especially its new respiratory drug line-up including recently launched Breo, Anoro and Incruse. New products account for just £2bn in annual sales, but with continued sales growth and additional launches, sales could rise to £6bn by 2018.

Meanwhile, investors are being handsomely rewarded for their patience, with shares in the pharma giant currently yielding 5.5%. There’s one major short-term negative: with the dividend being frozen at 80p per share for 2016 and 2017, there’s no dividend growth for at least two years.

Transition

Pearson (LSE: PSON) is going through a rough patch, reporting a 2% drop in adjusted operating profits in 2015 and management giving a weak set of guidance figures for 2016. Adjusted operating profits are expected to come between £580m and £620m in 2016, which at the mid-point implies a decline of 13% on the previous year.

There are causes for optimism though. Pearson‘s competitive position is strong, and cyclical and policy factors are mainly to blame for recent weakness. This included a buoyant employment market in the US, which meant reduced college enrolment, and policy changes in the UK that lowered demand for its vocational course services.

The outlook in the longer term remains attractive. Pearson has significant exposure to growing markets in Brazil, China, India and South Africa, where it’s launching new products such as the New Student Experience. Its transition from print to digital would also likely be positive to its competitive position, given the advantage scale has on digital platforms.

With an annual dividend of 52p per share, Pearson yields 6%.

Market leader

Investor confidence in G4S (LSE: GFS) is near an all-time low, with the company seemingly embroiled in an endless list of controversies, ranging from overcharging of government contracts, human rights violations and abuse at a young offenders centre. But the company is still set to deliver strong underlying growth in revenues and earnings.

G4S remains global market leader in security services and against the backdrop of global economic uncertainty, demand for its services remains robust. In 2015, it secured new contract sales worth £2.4bn with retention rates near 90%. This shows the company has little trouble in winning new contracts even after recent scandals.

City analysts expect underlying EPS will grow 5.6% this year, to 15.2p per share. For 2017, earnings should climb another 9%, to 16.6p. This would put the shares on an attractive forward P/E of 12.2 and 11.2, respectively.

The stock’s 5.1% yield isn’t as big, but there’s potential for faster future dividend growth, given that earnings growth is set to accelerate.

Jack Tang has no position in any shares mentioned. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Man hanging in the balance over a log at seaside in Scotland
Investing Articles

£5,000 to invest? Consider 5 no-brainer dividend shares with over 20 years of growth

These UK dividend shares have some of the longest track records of consistent growth, making them a dream for passive…

Read more »

Passive income text with pin graph chart on business table
Investing Articles

How to build passive income starting with just £3 a day

Starting with only £3 a day, it's possible to build a pot worth £200,000 over decades. But which investments does…

Read more »

Investing Articles

£5,000 invested in Tesco shares at the start of 2025 is now worth…

Tesco shares have enjoyed a very strong run over the past couple of years. But where next for this FTSE…

Read more »

Night Takeoff Of The American Space Shuttle
Investing Articles

4 dirt-cheap growth shares to consider for 2026!

Discover four top growth shares that could take off in the New Year -- and why our writer Royston Wild…

Read more »

Road 2025 to 2032 new year direction concept
Investing Articles

I asked ChatGPT how to start investing in UK shares with just £500 and it said do this

Harvey Jones asks artificial intelligence a few questions about how to get started in investing, before giving up and deciding…

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Dividend Shares

Yielding 10.41%, is this the best dividend share in the FTSE 250?

Jon Smith points out a dividend share with a double-digit yield, but explains why digging below the surface provides important…

Read more »

Investing Articles

Is 2026 the year it all goes wrong for the Rolls-Royce share price?

2025 has been another stellar year for the Rolls-Royce share price but Harvey Jones wonders just how long its magnificent…

Read more »

Night Takeoff Of The American Space Shuttle
Investing Articles

A SpaceX IPO could light a fire under this FTSE 100 stock

Shareholders of this FTSE 100 investment trust may have just got an early Christmas present from Space Exploration Technologies (SpaceX).

Read more »